


Research Transparency Panel Meeting Summary

Takeda Pharmaceuticals (“Takeda”)

4th June 2024

4 – 5.30pm



Data Access Proposal Request

Flatiron Health UK RWD Products

- Flatiron Colorectal Cancer data product

Attendees

FLATIRON HEALTH UK

- Adam Manhi (chair)
- Emma Salib (programme manager)

RESEARCH TRANSPARENCY PANEL

- Jennifer McCaffery (lay)
- Kaeden Bunting (lay)
- Thomas Smith (patient)
- Trishna Bharadia (patient)
- Shira Peleg Hasson (clinical)

Conflicts of interest

No conflicts declared by panel

Decision outcome

Approved

Summary of discussion

- Broad agreement the proposal, though complex, is well set out with clear goals for accessing real-world data.
- Clear alignment between teams requiring access, use cases, target outputs and proposed activities. Good examples of target outputs (e.g. ESMO conference).
- Well written lay summary - good overview of company, the drug, evidence to date and future aspirations.
- Section on planned activities is very clear, providing excellent rationale behind the data analysis and the need to identify real world survival rates.
- The panel raised several comments on other aspects of the application including:
 - Capturing additional details in the lay summary (e.g. % of population with metastatic colorectal cancer; survival rates; existing therapies).
 - Elaborating further on how findings will be disseminated to patients.